Cargando…

ERK Signaling Pathway Is Constitutively Active in NT2D1 Non-Seminoma Cells and Its Inhibition Impairs Basal and HGF-Activated Cell Proliferation

c-MET/hepatocyte growth factor (HGF) system deregulation is a well-known feature of malignancy in several solid tumors, and for this reason this system and its pathway have been considered as potential targets for therapeutic purposes. In previous manuscripts we reported c-MET/HGF expression and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gesualdi, Luisa, Berardini, Marika, Scicchitano, Bianca Maria, Castaldo, Clotilde, Bizzarri, Mariano, Filippini, Antonio, Riccioli, Anna, Schiraldi, Chiara, Ferranti, Francesca, Liguoro, Domenico, Mancini, Rita, Ricci, Giulia, Catizone, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377482/
https://www.ncbi.nlm.nih.gov/pubmed/37509533
http://dx.doi.org/10.3390/biomedicines11071894
_version_ 1785079528678227968
author Gesualdi, Luisa
Berardini, Marika
Scicchitano, Bianca Maria
Castaldo, Clotilde
Bizzarri, Mariano
Filippini, Antonio
Riccioli, Anna
Schiraldi, Chiara
Ferranti, Francesca
Liguoro, Domenico
Mancini, Rita
Ricci, Giulia
Catizone, Angela
author_facet Gesualdi, Luisa
Berardini, Marika
Scicchitano, Bianca Maria
Castaldo, Clotilde
Bizzarri, Mariano
Filippini, Antonio
Riccioli, Anna
Schiraldi, Chiara
Ferranti, Francesca
Liguoro, Domenico
Mancini, Rita
Ricci, Giulia
Catizone, Angela
author_sort Gesualdi, Luisa
collection PubMed
description c-MET/hepatocyte growth factor (HGF) system deregulation is a well-known feature of malignancy in several solid tumors, and for this reason this system and its pathway have been considered as potential targets for therapeutic purposes. In previous manuscripts we reported c-MET/HGF expression and the role in testicular germ cell tumors (TGCTs) derived cell lines. We demonstrated the key role of c-Src and phosphatidylinositol 3-kinase (PI3K)/AKT adaptors in the HGF-dependent malignant behavior of the embryonal carcinoma cell line NT2D1, finding that the inhibition of these onco-adaptor proteins abrogates HGF triggered responses such as proliferation, migration, and invasion. Expanding on these previous studies, herein we investigated the role of mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase (ERK) pathways in the HGF-dependent and HGF-independent NT2D1 cells biological responses. To inhibit MAPK/ERK pathways we chose a pharmacological approach, by using U0126 inhibitor, and we analyzed cell proliferation, collective migration, and chemotaxis. The administration of U0126 together with HGF reverts the HGF-dependent activation of cell proliferation but, surprisingly, does not exert the same effect on NT2D1 cell migration. In addition, we found that the use of U0126 alone significantly promotes the acquisition of NT2D1 «migrating phenotype», while collective migration of NT2D1 cells was stimulated. Notably, the inhibition of ERK activation in the absence of HGF stimulation resulted in the activation of the AKT-mediated pathway, and this let us speculate that the paradoxical effects obtained by using U0126, which are the increase of collective migration and the acquisition of partial epithelium–mesenchyme transition (pEMT), are the result of compensatory pathways activation. These data highlight how the specific response to pathway inhibitors, should be investigated in depth before setting up therapy.
format Online
Article
Text
id pubmed-10377482
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103774822023-07-29 ERK Signaling Pathway Is Constitutively Active in NT2D1 Non-Seminoma Cells and Its Inhibition Impairs Basal and HGF-Activated Cell Proliferation Gesualdi, Luisa Berardini, Marika Scicchitano, Bianca Maria Castaldo, Clotilde Bizzarri, Mariano Filippini, Antonio Riccioli, Anna Schiraldi, Chiara Ferranti, Francesca Liguoro, Domenico Mancini, Rita Ricci, Giulia Catizone, Angela Biomedicines Article c-MET/hepatocyte growth factor (HGF) system deregulation is a well-known feature of malignancy in several solid tumors, and for this reason this system and its pathway have been considered as potential targets for therapeutic purposes. In previous manuscripts we reported c-MET/HGF expression and the role in testicular germ cell tumors (TGCTs) derived cell lines. We demonstrated the key role of c-Src and phosphatidylinositol 3-kinase (PI3K)/AKT adaptors in the HGF-dependent malignant behavior of the embryonal carcinoma cell line NT2D1, finding that the inhibition of these onco-adaptor proteins abrogates HGF triggered responses such as proliferation, migration, and invasion. Expanding on these previous studies, herein we investigated the role of mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase (ERK) pathways in the HGF-dependent and HGF-independent NT2D1 cells biological responses. To inhibit MAPK/ERK pathways we chose a pharmacological approach, by using U0126 inhibitor, and we analyzed cell proliferation, collective migration, and chemotaxis. The administration of U0126 together with HGF reverts the HGF-dependent activation of cell proliferation but, surprisingly, does not exert the same effect on NT2D1 cell migration. In addition, we found that the use of U0126 alone significantly promotes the acquisition of NT2D1 «migrating phenotype», while collective migration of NT2D1 cells was stimulated. Notably, the inhibition of ERK activation in the absence of HGF stimulation resulted in the activation of the AKT-mediated pathway, and this let us speculate that the paradoxical effects obtained by using U0126, which are the increase of collective migration and the acquisition of partial epithelium–mesenchyme transition (pEMT), are the result of compensatory pathways activation. These data highlight how the specific response to pathway inhibitors, should be investigated in depth before setting up therapy. MDPI 2023-07-04 /pmc/articles/PMC10377482/ /pubmed/37509533 http://dx.doi.org/10.3390/biomedicines11071894 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gesualdi, Luisa
Berardini, Marika
Scicchitano, Bianca Maria
Castaldo, Clotilde
Bizzarri, Mariano
Filippini, Antonio
Riccioli, Anna
Schiraldi, Chiara
Ferranti, Francesca
Liguoro, Domenico
Mancini, Rita
Ricci, Giulia
Catizone, Angela
ERK Signaling Pathway Is Constitutively Active in NT2D1 Non-Seminoma Cells and Its Inhibition Impairs Basal and HGF-Activated Cell Proliferation
title ERK Signaling Pathway Is Constitutively Active in NT2D1 Non-Seminoma Cells and Its Inhibition Impairs Basal and HGF-Activated Cell Proliferation
title_full ERK Signaling Pathway Is Constitutively Active in NT2D1 Non-Seminoma Cells and Its Inhibition Impairs Basal and HGF-Activated Cell Proliferation
title_fullStr ERK Signaling Pathway Is Constitutively Active in NT2D1 Non-Seminoma Cells and Its Inhibition Impairs Basal and HGF-Activated Cell Proliferation
title_full_unstemmed ERK Signaling Pathway Is Constitutively Active in NT2D1 Non-Seminoma Cells and Its Inhibition Impairs Basal and HGF-Activated Cell Proliferation
title_short ERK Signaling Pathway Is Constitutively Active in NT2D1 Non-Seminoma Cells and Its Inhibition Impairs Basal and HGF-Activated Cell Proliferation
title_sort erk signaling pathway is constitutively active in nt2d1 non-seminoma cells and its inhibition impairs basal and hgf-activated cell proliferation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377482/
https://www.ncbi.nlm.nih.gov/pubmed/37509533
http://dx.doi.org/10.3390/biomedicines11071894
work_keys_str_mv AT gesualdiluisa erksignalingpathwayisconstitutivelyactiveinnt2d1nonseminomacellsanditsinhibitionimpairsbasalandhgfactivatedcellproliferation
AT berardinimarika erksignalingpathwayisconstitutivelyactiveinnt2d1nonseminomacellsanditsinhibitionimpairsbasalandhgfactivatedcellproliferation
AT scicchitanobiancamaria erksignalingpathwayisconstitutivelyactiveinnt2d1nonseminomacellsanditsinhibitionimpairsbasalandhgfactivatedcellproliferation
AT castaldoclotilde erksignalingpathwayisconstitutivelyactiveinnt2d1nonseminomacellsanditsinhibitionimpairsbasalandhgfactivatedcellproliferation
AT bizzarrimariano erksignalingpathwayisconstitutivelyactiveinnt2d1nonseminomacellsanditsinhibitionimpairsbasalandhgfactivatedcellproliferation
AT filippiniantonio erksignalingpathwayisconstitutivelyactiveinnt2d1nonseminomacellsanditsinhibitionimpairsbasalandhgfactivatedcellproliferation
AT ricciolianna erksignalingpathwayisconstitutivelyactiveinnt2d1nonseminomacellsanditsinhibitionimpairsbasalandhgfactivatedcellproliferation
AT schiraldichiara erksignalingpathwayisconstitutivelyactiveinnt2d1nonseminomacellsanditsinhibitionimpairsbasalandhgfactivatedcellproliferation
AT ferrantifrancesca erksignalingpathwayisconstitutivelyactiveinnt2d1nonseminomacellsanditsinhibitionimpairsbasalandhgfactivatedcellproliferation
AT liguorodomenico erksignalingpathwayisconstitutivelyactiveinnt2d1nonseminomacellsanditsinhibitionimpairsbasalandhgfactivatedcellproliferation
AT mancinirita erksignalingpathwayisconstitutivelyactiveinnt2d1nonseminomacellsanditsinhibitionimpairsbasalandhgfactivatedcellproliferation
AT riccigiulia erksignalingpathwayisconstitutivelyactiveinnt2d1nonseminomacellsanditsinhibitionimpairsbasalandhgfactivatedcellproliferation
AT catizoneangela erksignalingpathwayisconstitutivelyactiveinnt2d1nonseminomacellsanditsinhibitionimpairsbasalandhgfactivatedcellproliferation